Other languages Myriad Genetics, Inc.

Equities

MYGN

US62855J1043

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
25.47 ^USD	+0.87%		+30.82%	+33.07%

May. 08	Sector Update: Health Care Stocks Softer Late Afternoon	MT
May. 08	Myriad Genetics Shares Rise After Reporting Narrower Q1 Adjusted Loss, Higher Revenue	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Softer Late Afternoon	May. 08
Myriad Genetics Shares Rise After Reporting Narrower Q1 Adjusted Loss, Higher Revenue	May. 08
Eurobio Scientific : accord avec Myriad Genetics	May. 08
Eurobio Scientific to Buy Gene Expression Test for Breast Cancer	May. 08
Myriad Genetics to Seek Acquisitions	May. 07
Myriad Genetics, Inc. Reiterates Earnings Guidance for the Full Year 2024	May. 07
Myriad Genetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07
Myriad Genetics, Inc. Provides Revenue Guidance for the First Quarter 2024	Feb. 27
Myriad Genetics, Inc. Updates Revenue Guidance for the Fiscal Year 2024	Feb. 27
Myriad Genetics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27
Myriad Genetics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27
Myriad Genetics Acquires Intermountain Precision Genomics' Assets from Intermountain Health	Feb. 01
Myriad Genetics, Inc. completed the acquisition of select assets of laboratory business of Intermountain Precision Genomics.	Jan. 31
Myriad Genetics, Inc. Appoints George Daneker as President and Chief Clinical Officer of Oncology, Effective March 18, 2024	Jan. 30
Myriad Genetics Agrees to Acquire Select Assets of Intermountain Precision Genomics' Laboratory Business	Jan. 19
Myriad Genetics Names Scott Leffler as Chief Financial Officer, Reiterates Outlook	Dec. 21
Myriad Genetics, Personalis Collaborate to Market ImmunoID NeXT Platform	Nov. 16
Myriad Genetics, Inc. and Personalis, Inc. Partner to Market Solutions to Pharma Customers	Nov. 16
Myriad Genetics Shares Climb as Q3 Loss Narrower Than Estimated, FY Revenue Guidance Raised	Nov. 07
Myriad Genetics, Inc. Provides Financial Guidance for 2023 and 2024	Nov. 06

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Myriad Genetics, Inc.

Equities

MYGN

US62855J1043

Other languages

Filters